BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//SciLifeLab - ECPv6.15.18//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:SciLifeLab
X-ORIGINAL-URL:https://www.scilifelab.se
X-WR-CALDESC:Events for SciLifeLab
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Europe/Stockholm
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20200329T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20201025T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20210328T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20211031T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20220327T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20221030T010000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20210526T150000
DTEND;TZID=Europe/Stockholm:20210526T160000
DTSTAMP:20260404T003838
CREATED:20210428T095007Z
LAST-MODIFIED:20210602T140817Z
UID:53113-1622041200-1622044800@www.scilifelab.se
SUMMARY:Role of physiologically-based pharmacokinetics in regulatory submissions
DESCRIPTION:Fabienne Gaugaz Slides from the webinarDownload\n\n\n\nLuzon et al\, 2017Download\n\n\n\nAbstractPhysiologically based pharmacokinetic (PBPK) is an approach that help predict the absorption\, distribution\, metabolism and excretion (ADME) properties of candidate drugs in animal/human and evaluate the effects of intrinsic (e.g. organ dysfunction\, age\, genetics) and extrinsic (e.g. diet\, smoking habit\, drug-drug interactions) factors\, alone or in combinations\, on drug exposure\, during drug discovery and development process. Currently\, different software (i.e. SimCYP\, PK-Sim\, GastroPlus etc) are available to perform the PBPK simulations\, and the simulations are often part of regulatory submissions of small molecules and biologic new drug candidates (CD). \n\n\n\nIf successful\, the simulations may complement or replace the experimental study and/or help to explain different findings\, scenarios related to estimation of exposure and effect of new CDs. Therefore\, the regulatory authorities i.e. EMA and FDA provided guidelines\, which described how to report PBPK models and simulations in a regulatory context.Dr Gaugaz in her presentation will discuss role of PBPK simulations from small molecules and biologic CDs in submissions\, from regulatory point of view. \n\n\n\nPresenterDr Fabienne GaugazPharmacokinetics Assessor\,Medical Products Agency (Läkemedelsverket)Dag Hammarskjölds Väg 42\,752 37 Uppsala \n\n\n\nBiographyDr Fabienne Gaugaz is pharmacokinetics assessor at the Swedish Medical Product Agency (Läkemedelsverket)\, which entails the evaluation of the pharmacologically-based pharmacokinetics (PBPK) simulations related to small molecules and biologic drug candidates. Dr Gaugaz previously worked at Bayer (Wuppertal\, Germany) as lab head of research pharmacokinetics. Fabienne made her postdoc project at Karolinska Institutet (KI) and Uppsala University (UU). Dr Gaugaz obtained her Ph.D. in 2013 in pharmaceutical biology at the Institute of Pharmaceutical Sciences\, Swiss Federal Institute of Technology (ETH) in Zürich\, Switzerland and her M.Sc. in Pharmacy\, ETH\, Zürich\, Switzerland.
URL:https://www.scilifelab.se/event/role-of-physiologically-based-pharmacokinetics-in-regulatory-submissions/
CATEGORIES:Event
LOCATION:
END:VEVENT
END:VCALENDAR